What is the address of MEDICOPRECIS?

The registered office of MEDICOPRECIS is located at Bosstraat 53, 9830 Sint-Martens-Latem.

Is MEDICOPRECIS still active?

Yes. According to the CBE (30 October 2026) MEDICOPRECIS is active, legal situation “Normale toestand”, started on 28 December 1983.

Is MEDICOPRECIS registered on Peppol?

Yes, MEDICOPRECIS is registered on the Peppol network with ID 0208:0425863454.

What is the enterprise number of MEDICOPRECIS?

The enterprise number of MEDICOPRECIS is BE0425863454.

When was MEDICOPRECIS founded?

MEDICOPRECIS was founded on 28 December 1983.

Who are the directors of MEDICOPRECIS?

According to the 2025 annual accounts, the directors of MEDICOPRECIS are: Martine Rooze, Sébastien De la haye.

Is MEDICOPRECIS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 December 1983; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did MEDICOPRECIS make in 2025?

MEDICOPRECIS recorded a loss after taxes of € 43,094 in financial year 2025.

What is the revenue of MEDICOPRECIS?

As a small company, MEDICOPRECIS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 4,304.

MEDICOPRECIS (Public Limited) - Sint-Martens-Latem

Dossier MEDICOPRECIS, printed on 30 October 2026 from databakkes.be/en/0425863454/medicoprecis. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 10 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

MEDICOPRECIS from Sint-Martens-Latem, company number BE0425863454, closed financial year 2025 with a result of € -43,094 after tax. For that financial year MEDICOPRECIS recorded a gross margin of € 4,304 and equity of € 173,849. Compared with financial year 2024, the result moved from € -43,195 to € -43,094. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.

What it is worth Healthy

€ 173,849

▼ 20% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -43,094

Profit after tax over the fiscal year.

Cash in the bank

€ 3,102

▲ € 2,732 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -2.1 million.

Debts at end 2025

Bank debt

€ 450,769

▼ 5% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 10,893

▲ € 8,603 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 9,083 Gross margin 2022: € 9,083 First fiscal year in the series	€ 2,174 Gross margin 2023: € 2,174 ▼ 76% vs 2022 (€ 9,083) Unfavourable step	€ 4,599 Gross margin 2024: € 4,599 ▲ 112% vs 2023 (€ 2,174) Favourable step	€ 4,304 Gross margin 2025: € 4,304 ▼ 6% vs 2024 (€ 4,599) Unfavourable step	▼ 6%
Profit after taxes	€ -37,784 Profit after taxes 2022: € -37,784 First fiscal year in the series	€ -45,445 Profit after taxes 2023: € -45,445 ▼ € 7,661 vs 2022 (€ -37,784) Unfavourable step	€ -43,195 Profit after taxes 2024: € -43,195 ▲ € 2,250 vs 2023 (€ -45,445) Favourable step	€ -43,094 Profit after taxes 2025: € -43,094 Unchanged (€ -43,195) Favourable step
Equity	€ 305,583 Equity 2022: € 305,583 First fiscal year in the series	€ 260,138 Equity 2023: € 260,138 ▼ 15% vs 2022 (€ 305,583) Unfavourable step	€ 216,943 Equity 2024: € 216,943 ▼ 17% vs 2023 (€ 260,138) Unfavourable step	€ 173,849 Equity 2025: € 173,849 ▼ 20% vs 2024 (€ 216,943) Unfavourable step	▼ 20%
Total debts	€ 514,048 Total debts 2022: € 514,048 First fiscal year in the series	€ 491,451 Total debts 2023: € 491,451 ▼ 4% vs 2022 (€ 514,048) Favourable step	€ 476,030 Total debts 2024: € 476,030 ▼ 3% vs 2023 (€ 491,451) Favourable step	€ 481,662 Total debts 2025: € 481,662 ▲ 1% vs 2024 (€ 476,030) Unfavourable step	▲ 1%
Cash	€ 387 Cash 2022: € 387 First fiscal year in the series	€ 291 Cash 2023: € 291 ▼ 25% vs 2022 (€ 387) Unfavourable step	€ 370 Cash 2024: € 370 ▲ 27% vs 2023 (€ 291) Favourable step	€ 3,102 Cash 2025: € 3,102 ▲ € 2,732 vs 2024 (€ 370) Favourable step	▲ € 2,732
Land & buildings	€ 825,707 Land & buildings 2022: € 825,707 First fiscal year in the series	€ 781,456 Land & buildings 2023: € 781,456 ▼ 5% vs 2022 (€ 825,707) Unchanged	€ 737,205 Land & buildings 2024: € 737,205 ▼ 6% vs 2023 (€ 781,456) Unchanged	€ 692,955 Land & buildings 2025: € 692,955 ▼ 6% vs 2024 (€ 737,205) Unchanged	▼ 6%
Retained profit	€ -1,994,417 Retained profit 2022: € -1,994,417 First fiscal year in the series	€ -2,039,862 Retained profit 2023: € -2,039,862 ▼ € 45,445 vs 2022 (€ -1,994,417) Unfavourable step	€ -2,083,057 Retained profit 2024: € -2,083,057 ▼ € 43,195 vs 2023 (€ -2,039,862) Unfavourable step	€ -2,126,151 Retained profit 2025: € -2,126,151 ▼ € 43,094 vs 2024 (€ -2,083,057) Unfavourable step	▼ € 43,094
Bank debt	€ 510,386 Bank debt 2022: € 510,386 First fiscal year in the series	€ 483,899 Bank debt 2023: € 483,899 ▼ 5% vs 2022 (€ 510,386) Favourable step	€ 473,740 Bank debt 2024: € 473,740 ▼ 2% vs 2023 (€ 483,899) Favourable step	€ 450,769 Bank debt 2025: € 450,769 ▼ 5% vs 2024 (€ 473,740) Favourable step	▼ 5%
Balance sheet total	€ 872,360 Balance sheet total 2022: € 872,360 First fiscal year in the series	€ 800,263 Balance sheet total 2023: € 800,263 ▼ 8% vs 2022 (€ 872,360) Unchanged	€ 737,591 Balance sheet total 2024: € 737,591 ▼ 8% vs 2023 (€ 800,263) Unchanged	€ 696,072 Balance sheet total 2025: € 696,072 ▼ 6% vs 2024 (€ 737,591) Unchanged	▼ 6%

Key figures of MEDICOPRECIS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to MEDICOPRECIS?

What happened at MEDICOPRECIS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2031 Martine Rooze stepped down as director. NBB
2031 Sébastien De la haye stepped down as director. NBB
Jun 29, 2026 New annual accounts for financial year 2025: loss of € 43,094. Source: NBB ↗
2025 Martine Rooze became a director. NBB
2025 Sébastien De la haye became a director. NBB
Jun 6, 1984 New establishment in Sint-Martens-Latem. KBO
Dec 28, 1983 Start of the company according to the CBE. KBO

In short

From € 37,784 loss in 2022 to € 43,094 loss in 2025.

Original PDFs at the National Bank ↗

Management

Directors

According to the 2025 annual accounts

Martine Rooze

Director

since 2025 · until 2031

Sébastien De la haye

Managing director

since 2025 · until 2031

Establishments

Establishment units

Physical locations of this company

Registered office

Bosstraat 53

9830 Sint-Martens-Latem

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0425.863.454
VAT number: BE 0425.863.454
Registered office: Bosstraat 53, 9830 Sint-Martens-Latem
Names & denominations: MEDICOPRECIS
Enterprise type: Rechtspersoon
Legal form: Public limited company
Legal situation: Normale toestand
Start date: 28 December 1983
Peppol: Active · Active since 24 Jan 2026

View on CBE Public ↗ Annual accounts (NBB) ↗

MEDICOPRECIS